Trial reportBMC cancer2025
Preliminary experience of lenvatinib, tislelizumab and transcatheter arterial chemoembolization for BCLC stage C hepatocellular carcinoma: a phase II study.
Trial report in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05131698 (Clinical Study of the Efficacy and Safety of Transhepatic Arterial Chemoembolization Combined With Tislelizumab and Lenvatinib in Patients With Advanced Unresectable Hepatocellular Carcinoma), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Clinical Study of the Efficacy and Safety of Transhepatic Arterial Chemoembolization Combined With Tislelizumab and Lenvatinib in Patients With Advanced Unresectable Hepatocellular Carcinoma
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThis study evaluated the efficacy and safety of the triple combination of transcatheter arterial chemoembolization (TACE), lenvatinib, and tislelizumab in patients with advanced unresectable hepatocellular carcinoma.
methodsPatients with confirmed HCC in Barcelona Clinic Liver Cancer stage C were included. Patients were initially treated with TACE, followed by intravenous tislelizumab (200 mg, IV) every 21 days and lenvatinib (8 or 12 mg/day) once daily. The primary endpoint was objective response rate based on the modified Response Evaluation Criteria in Solid Tumors (mRECIST). The secondary endpoints included disease control rate based on mRECIST, objective response rate and disease control rate based on the Response Evaluation Criteria in Solid Tumors (version 1.1), overall survival (OS), progression-free survival (PFS), time to progression (TTP), duration of response (DOR), and safety. An exploratory endpoint was systemic immune-inflammation index (SII).
resultsThirty-one patients with advanced unresectable HCC were enrolled. The objective response rate was 74.2% and disease control rate was 87.1% based on mRECIST. The median OS was 12.6 months and median PFS was 6.5 months. The median TTP was 8.2 months, and median DOR was 7.3 months. Treatment-related adverse events occurred in 64.5% of patients, and most events were grade1-2. The rate of grade ≥3 events was 19.4%. Overall survival and progression-free survival after triple therapy were better in patients with lower SII at baseline.
conclusionThe combination of TACE, lenvatinib, and tislelizumab can be effective against advanced unresectable HCC, leading to a relatively high objective response rate and tolerable safety profile. SII may be useful for predicting response to this triple therapy.
trial registrationClinicalTrials.gov identifier: NCT05131698, registered 4 November 2021.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.